• 实验研究 • Previous Articles Next Articles
Received:
Revised:
Published:
Online:
Abstract: 【Abstract】Objective:To investigate the inhibition and the mechanism of endostatin on the growth of human cervical cancer in nude mice. Methods: Thirty mice of cervical cancer model were established by left anterior subcutaneous inoculation.After 1 week of transplantation,model mice were randomly divided into three groups ( twenty in each) including PBS control group, Empty virus group and rAAV-ES group . The weight of nude mice and tumor size were measured every other day. Calculate the tumor volume and draw tumor growth curve, After 3 weeks of treatment, mice were killed by cervical dislocation,the tumor was removed and the volume and weight of tumor were measured. The tumor inhibition rate was calculated.HE staining was used to observe the tumor cells morphology.The expressions of Bcl-2、Bax and Caspase-3 in the transplanted tumor were detected by immunohistochemistry. Results:Nude Mice model of cervical cancer were established successfully. Compared with the control group and Empty virus group, the tumor growth slow down significantly in rAAV-ES group, the tumor inhibition rate was 62.55% . Immunohistochemistry showed,the positive rate of Bcl-2 expression was 35% in endostatin group,much lower than that in other two groups(80% and 85%,P﹤0.01).The positive rate of Bax expression had no significant change among the three groups.But the Bcl-2/Bax ratio was lower.The positive rate of Caspase-3 expression was 70% in endostatin group,much higher than that in other two groups(20% and 25%,P﹤0.01);The expression of Bcl-2 is negatively correlated with that of Caspase-3(r=-0.653,P<0.01).Conclusions: rAAV-ES may be through down-regulating Bcl-2 protein, lowering Bcl-2/Bax ratio, activating the downstream Caspase-3 to induce cell apoptosis, thus inhibit tumor growth.
Key words: endostatin, Bcl-2, Bax, Caspase-3, cervical cancer
/ Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.tjyybjb.ac.cn/EN/
https://www.tjyybjb.ac.cn/EN/Y2011/V39/I3/256